Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of thumbtack needle therapy on sleep in women with chronic insomnia during perimenopause and menopause. This multicenter, randomized, controlled, and blinded trial involves 198 women aged 40 to 65 years. The study aims to compare the effects of thumbtack needle treatment with placebo thumbtack needle treatment over a 4-week period. Participants are randomly assigned to one of two groups the treatment group receives thumbtack needle therapy at 11 specific acupoints, and the control group receives placebo thumbtack needle therapy at the same acupoints with comforting acupressure. Treatments are given twice a week, with needles retained for 3 days before removal and skin disinfection. Patients rest one day between treatments, completing a total 4-week course. During the study, participants will be assessed using multiple sleep-related scales and indexes such as the Insomnia Severity Index, Pittsburgh Sleep Quality Index, and Epworth Sleepiness Scale, among others. Researchers will monitor sleep efficiency, wake times, hormone levels, and insomnia remission rates. Safety and treatment response will be evaluated throughout the 4 weeks, with the primary outcome measured by the Insomnia Severity Index at 4 weeks.
Actively Recruiting
Researchers are evaluating the effect, safety, and cost-effectiveness of low-sodium salt substitutes in reducing blood pressure and preventing hypertensive disorders in pregnant women at high risk in China. This study will enroll about 3,200 pregnant women at or before 16 weeks of gestation from multiple hospitals across several provinces. The trial uses an adaptive two-phase design, with an interim analysis after the first 400 participants to decide on continuation and sample size adjustments. Participants will be randomly assigned in equal groups to either use a potassium-enriched salt substitute containing 25% potassium chloride and 75% sodium chloride or continue using usual salt with over 99% sodium chloride. The assigned salt will be provided free of charge and used for home-prepared meals until delivery. Follow-up will continue through all antenatal visits and delivery to collect blood pressure data and monitor the incidence of hypertensive disorders and related adverse events. Participants will attend regular antenatal check-ups where blood pressure and other health data will be collected. The primary outcomes include the change in systolic blood pressure from baseline to about 36-37 weeks gestation and the incidence of new hypertensive disorders and maternal adverse events from randomization to delivery. Researchers will also assess safety, adherence, and cost-effectiveness during the study, which continues until delivery for each participant.
Actively Recruiting
Nausea and vomiting in pregnancy NVP is a common and challenging problem during the first trimester, affecting the quality of life for many pregnant women. This research aims to evaluate the clinical effectiveness and safety of thumbtack needle TN therapy, a type of acupuncture, for treating NVP. The study is a multi-center, large-sample, randomized, controlled, and triple-blinded clinical trial designed to provide high-quality evidence on this treatment. The trial compares thumbtack needle therapy with a sham thumbtack needle treatment. TN involves applying small intradermal needles to specific acupuncture points, which are kept in place for 3 days with patients pressing the needles multiple times daily. Treatments occur every 3 days for a total of 5 sessions over 15 days. The sham treatment mimics the procedure without actual needle penetration and without pressing during retention. Participants will be closely monitored throughout the study with assessments including nausea and vomiting severity, quality of life, anxiety, depression, sleep quality, weight changes, blood tests for electrolytes, liver and kidney function, thyroid hormones, and pregnancy and neonatal outcomes. Safety and patient satisfaction will also be evaluated. The primary outcome is the change in nausea and vomiting severity measured by the PUQE scale from baseline to day 15. Follow-up continues up to 42 days postpartum to observe pregnancy complications and neonatal health.